East Bay company eyes first drug approval after decade-long journey


The company has burned through $400 million, laid off employees and lost two Big Pharma partnerships, but now it is near an FDA drug approval for people with a debilitating bowel disorder.

Previous Woodlands-based pharma co. to receive $260M in drug dispute settlement
Next Bayer to lay off hundreds in Pittsburgh